Skip to content
LATEST
Health

Australian Regulators Approve Daily Oral GLP-1 Weight-Loss Medication

Australian regulators have approved a daily oral GLP-1 weight-loss drug, with market availability expected by year-end despite ongoing uncertainty regarding…

Australian Regulators Approve Daily Oral GLP-1 Weight-Loss Medication

The Therapeutic Goods Administration has approved the sale of daily oral semaglutide tablets for chronic weight management. The medication is indicated for adults with a body mass index of 30 or higher, or those with a BMI of 27 to 30 presenting with weight-related comorbidities.

Clinical administration requires a 16-week dose escalation protocol, alongside dietary and physical activity interventions. The drug is also approved for reducing the risk of cardiovascular events, including heart attack and stroke.

Regulatory warnings highlight potential risks including gastrointestinal complications, renal failure, acute pancreatitis, and diabetic retinopathy. Animal studies have indicated a potential link to thyroid tumors, and reports exist regarding psychiatric side effects, including depression and suicidal ideation.

Market availability is expected by late 2026. Pricing remains unconfirmed, and the medication is not currently subsidized under Pharmaceutical Benefits Scheme, necessitating private funding for patients.

More stories

Latest news